Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Nivolumab + Bevacizumab + Rucaparib for Ovarian Cancer
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial tests three drugs for patients with relapsed ovarian, fallopian tube, or peritoneal cancer. Nivolumab helps the immune system fight cancer, Bevacizumab stops blood vessel growth, and Rucaparib blocks DNA repair in cancer cells. The goal is to find new treatment options for these patients. Bevacizumab has been approved for the treatment of advanced ovarian cancer and has shown effectiveness in prolonging survival in various studies.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.